Your browser doesn't support javascript.
loading
Psychometric properties of patient-reported outcomes Common Terminology Criteria for adverse events (PRO-CTCAE®) in breast cancer patients: The prospective observational multicenter VIP study.
Caminiti, Caterina; Maglietta, Giuseppe; Arenare, Laura; Di Liello, Raimondo; Migliaccio, Gessica; Barberio, Daniela; De Laurentiis, Michelino; Di Rella, Francesca; Nuzzo, Francesco; Pacilio, Carmen; Iodice, Giovanni; Orditura, Michele; Ciardiello, Fortunato; Di Bella, Sara; Cavanna, Luigi; Porta, Camillo; Giovanardi, Filippo; Ripamonti, Carla Ida; Bilancia, Domenico; Aprile, Giuseppe; Ruelle, Tommaso; Diodati, Francesca; Piccirillo, Maria Carmela; Iannelli, Elisabetta; Pinto, Carmine; Perrone, Francesco.
Afiliación
  • Caminiti C; Clinical and Epidemiological Research Unit, University Hospital, Parma, Italy.
  • Maglietta G; Clinical and Epidemiological Research Unit, University Hospital, Parma, Italy.
  • Arenare L; Clinical Trial Unit, Istituto Nazionale Tumori, IRCCS Fondazione G.Pascale, Napoli, Italy.
  • Di Liello R; Division of Medical Oncology, Ospedale del Mare, Napoli, Italy.
  • Migliaccio G; Departmental Structure of Clinical Psycho-oncology, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, Italy.
  • Barberio D; Departmental Structure of Clinical Psycho-oncology, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, Italy.
  • De Laurentiis M; Experimental and Clinical Senologic Oncology Unit, Istituto Nazionale Tumori, IRCCS Fondazione G.Pascale, Napoli, Italy.
  • Di Rella F; Experimental and Clinical Senologic Oncology Unit, Istituto Nazionale Tumori, IRCCS Fondazione G.Pascale, Napoli, Italy.
  • Nuzzo F; Experimental and Clinical Senologic Oncology Unit, Istituto Nazionale Tumori, IRCCS Fondazione G.Pascale, Napoli, Italy.
  • Pacilio C; Experimental and Clinical Senologic Oncology Unit, Istituto Nazionale Tumori, IRCCS Fondazione G.Pascale, Napoli, Italy.
  • Iodice G; Experimental and Clinical Senologic Oncology Unit, Istituto Nazionale Tumori, IRCCS Fondazione G.Pascale, Napoli, Italy.
  • Orditura M; Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy.
  • Ciardiello F; Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy.
  • Di Bella S; Medical Oncology, ASST Rhodense, Rho (MI), Italy.
  • Cavanna L; Medical Oncology, Ospedale Guglielmo da Saliceto, Piacenza, Italy.
  • Porta C; Interdisciplinary Department of Medicine, Università degli Studi 'A. Moro', Bari, Italy; Polyclinic Consortium University Hospital, Bari, Italy.
  • Giovanardi F; Medical Oncology, Ospedale Civile, Guastalla (RE), Italy.
  • Ripamonti CI; Supportive Care Unit, istituto Nazionale Tumori, IRCCS, Milano, Italy.
  • Bilancia D; Medical Oncology, Ospedale S.Carlo, Potenza, Italy.
  • Aprile G; Medical Oncology, Azienda ULSS 8 Nerica, Ospedale S.Bortolo, Vicenza, Italy.
  • Ruelle T; Medical Oncology, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties (DIMI), Università di Genova, Genova, Italy.
  • Diodati F; Clinical and Epidemiological Research Unit, University Hospital, Parma, Italy.
  • Piccirillo MC; Clinical Trial Unit, Istituto Nazionale Tumori, IRCCS Fondazione G.Pascale, Napoli, Italy.
  • Iannelli E; FAVO - Federazione Italiana delle Associazioni di Volontariato in Oncologia, Roma, Italy.
  • Pinto C; Medical Oncology, AUSL-IRCCS, Reggio Emilia, Italy.
  • Perrone F; Clinical Trial Unit, Istituto Nazionale Tumori, IRCCS Fondazione G.Pascale, Napoli, Italy. Electronic address: f.perrone@istitutotumori.na.it.
Breast ; 77: 103781, 2024 Jul 20.
Article en En | MEDLINE | ID: mdl-39059033
ABSTRACT
Patients' self-reporting is increasingly considered essential to measure quality-of-life and treatment-related side-effects. However, if multiple patient-reported instruments are used, redundancy may represent an overload for patients. Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) are a tool allowing direct patients' reporting of side-effects. We tested psychometric properties of a selected list of PRO-CTCAE items, in a cohort of 303 breast cancer patients, using validated instruments for quality of life assessment as anchors. The analysis of convergent validity with HADS (Hospital Anxiety and Depression Scale) and EORTC BR-23 sub-scales, and the analysis of responsiveness with the PGIC (Patients Global Impression of Change) score supported that a selected list of PRO-CTCAE symptoms might represent a standardized, agile tool for both research and practice settings to reduce patient burden without missing relevant information on patient perceptions. Among patients using digital devices, those with a higher education levels required shorter time to fulfil questionnaires. In conclusion, a selected list of PRO-CTCAE items can be considered as a standardized, agile tool for capturing crucial domains of side-effects and quality of life in patients with breast cancer. The study is registered on clinicaltrials.gov (NCT04416672).
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Breast Asunto de la revista: ENDOCRINOLOGIA / NEOPLASIAS Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Breast Asunto de la revista: ENDOCRINOLOGIA / NEOPLASIAS Año: 2024 Tipo del documento: Article